Skip to content
OpenCapital
Get started

4D Molecular Therapeutics FDMT Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

EyePoint, Inc. logo
EyePoint, Inc. EYPT
$0+100%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$602.22M+215%
Enterprise value$550.27M+574%
P/S6.8×-8,306×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 4D Molecular Therapeutics's increase (decrease) in contract liabilities and current deferred income?
4D Molecular Therapeutics (FDMT) reported increase (decrease) in contract liabilities and current deferred income of $1.38M in Q1 2026.
How has 4D Molecular Therapeutics's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
4D Molecular Therapeutics's increase (decrease) in contract liabilities and current deferred income increased by 9957.1% year-over-year, from -$14K to $1.38M.
What is the long-term trend for 4D Molecular Therapeutics's increase (decrease) in contract liabilities and current deferred income?
Over 3 years (2021 to 2025), 4D Molecular Therapeutics's increase (decrease) in contract liabilities and current deferred income has grown at a -76.0% compound annual growth rate (CAGR), from -$15.07M to -$209K.